TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00804869

Intervention type: DEVICE
Intervention: PalmScan A2000 ultrasonography system (Micro Medical Devices, Calabasas, CA)
Description: PalmScan biometric measurements

Intervention type: DEVICE
Intervention: Standard A-mode ultrasound (Eye Cubed™, Ellex, Adelaide, Australia).
Description: A-mode biometric measurements group
Study: NCT03251976

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: usual physician counseling on end of life care
Study: NCT01413178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Test dose (32 mg/m\^2) on day -9 then 130 mg/m\^2 by vein or adjusted dose on Days -7, -6, -5, and -4.
Study: NCT02974101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: registration of AdaptiveStim
Study: NCT02853630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participant will be instructed to take Metformin tablets as per instructions given by the physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Participant will be instructed to take one tablet of Vildagliptin 50mg per day, 30 minutes after breakfast in the morning and second tablet at night, 30 minutes after dinner
Study: NCT03247712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg IV q2wks or 480mg IV q4wks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg IV q2wks or 480mg IV q4wks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg IV q2wks or 480mg IV q4wks
Study: NCT01833117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID 119515A
Description: topical ocular drops
Study: NCT03247712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg IV q2wks or 480mg IV q4wks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgical Resection of Tumor
Study: NCT01833117

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blink® Tears
Description: topical ocular drops
Study: NCT00004074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABI-007/carboplatin/trastuzumab
Description: Given IV
Study: NCT03415087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sequential intrathecal injection
Description: intrathecal injection of fentanyl and hyperbaric bupivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sequential intrathecal injection
Description: intrathecal injection of fentanyl and hyperbaric bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperbaric bupivacaine
Description: intrathecal injection of intrathecal bupivacaine
Study: NCT01413178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70 mg/m2 by vein over 30 minutes minutes on Days -2 and -1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Quality of Life (QOL) questionnaire before starting the study drugs and then once every 4 weeks after the stem cell transplant, taking about 15 minutes to complete.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Quality of Life (QOL) questionnaire before starting the study drugs and then once every 4 weeks after the stem cell transplant, taking about 15 minutes to complete.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Approximately 5 mcg/kg/day subcutaneously beginning on Day +5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Approximately 5 mcg/kg/day subcutaneously beginning on Day +5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Melphalan
Description: 200 mg/m2 by vein over 30 minutes on Day -2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplant
Description: Stem cell infusion on Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplant
Description: Stem cell infusion on Day 0.
Study: NCT03942328

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study: NCT03247712

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgical Resection of Tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgical Resection of Tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgical Resection of Tumor

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation (5 days)
Description: 8Gy x 5 (Mon-Fri) GTV+3mm

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation (3 days)
Description: 8Gy x 3 (Monday, Wednesday, Friday) GTV+3mm
Study: NCT05969327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: oral supplementation of two different doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: oral supplementation of two different doses
Study: NCT03074942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab 3 mg/kg once / every 4 weeks during 24 weeks
Study: NCT03223636

Intervention type: DEVICE
Intervention: TMS
Description: We will use TMS with paired-pulse technique to activate corticospinal neurons in the primary motor cortex and motorneurons in the brainstem, respectively (Hallett 2007; Ugawa et al. 1991; Ugawa et al.1994). Two stimulations will be separated with various interstimulus intervals to produce collision on nerve fibers with different conduction velocity in the corticospinal tract. The conduction time on nerve fibers in the corticospinal tract with different conduction velocity will be identified and the distribution of these fibers will be calculated.

Intervention type: DEVICE
Intervention: MRI
Description: MRI exams will consist of several sessions including calibration, anatomic, and diffusion MRI scanning (Avram et al. 2013; Avram et al. 2016; Pierpaoli et al. 1996). Data in each exam will be acquired in the left or right forearm (PNS).
Study: NCT02895633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ecography
Description: Standard Doppler ultrasound and perfusion imaging after injection of Sonovue

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT scan
Description: With injection of Iomeron 400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: With injection of gadolinium (Multihance)
Study: NCT00084838

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Study: NCT03565471

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Standard echocardiography.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Standard echocardiography.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Standard echocardiography.

Intervention type: DIAGNOSTIC_TEST
Intervention: Right side catheterization
Description: Right side catheterization with the purpose of measuring pulmonary vascular pressures and blood saturation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Right side catheterization
Description: Right side catheterization with the purpose of measuring pulmonary vascular pressures and blood saturation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Right side catheterization
Description: Right side catheterization with the purpose of measuring pulmonary vascular pressures and blood saturation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise test
Description: Exercise test on a supine bicycle with gradual increase in work load while wearing a mask that measures ventilation, oxygen uptake, carbon dioxide release and respiratory exchange rate.

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise test
Description: Exercise test on a supine bicycle with gradual increase in work load while wearing a mask that measures ventilation, oxygen uptake, carbon dioxide release and respiratory exchange rate.

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise test
Description: Exercise test on a supine bicycle with gradual increase in work load while wearing a mask that measures ventilation, oxygen uptake, carbon dioxide release and respiratory exchange rate.

Intervention type: DIAGNOSTIC_TEST
Intervention: Holter monitor
Description: Holter monitor worn for 2 whole days registering heart rate.

Intervention type: DIAGNOSTIC_TEST
Intervention: Holter monitor
Description: Holter monitor worn for 2 whole days registering heart rate.

Intervention type: DIAGNOSTIC_TEST
Intervention: Holter monitor
Description: Holter monitor worn for 2 whole days registering heart rate.
Study: NCT03264170

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Prediction of pregnancy outcome
Description: The intervention group will receive the individualised prediction of their pregnancy (as a percentage). The prediction is calculated by a validated, accurate mathematical model using specific background information and ultrasound data for each participant.
Study: NCT01736384

Intervention type: PROCEDURE
Intervention: Gastric bypass or cholecystectomy
Study: NCT04518202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine patch
Description: 5% lidocaine patch applied at 6 hours before the scheduled office hysteroscopy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham patch
Description: Sham patch containing no study medication applied at 6 hours before the scheduled office hysteroscopy.
Study: NCT02599675

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 dissolved in olive oil, encapsuled
Study: NCT03247712

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation (3 days)
Description: 8Gy x 3 (Monday, Wednesday, Friday) GTV+3mm

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation (3 days)
Description: 8Gy x 3 (Monday, Wednesday, Friday) GTV+3mm
Study: NCT01812018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar administered at 7.5 mg/m2, intravenously (IV), on Day 1-14 every 21 days for up to 4-6 consecutive cycles
Study: NCT02599675

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive oil, encapsuled
Study: NCT01706679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATX-101 (10 mg/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATX-101 (20 mg/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin (400 mg)
Study: NCT03415087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric bupivacaine
Description: intrathecal injection of intrathecal bupivacaine
Study: NCT01812018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered at 1000 mg/m2, intravenously (IV), on Day 1 and Day 8, every 21 days for up to 4-6 consecutive cycles
Study: NCT03415087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: intrathecal injection of fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: intrathecal injection of fentanyl
Study: NCT02903784

Intervention type: DEVICE
Group type: OTHER
Intervention: fMRI
Description: Patient with grade 2 glioma and healthy volunteers use a brain imaging (fMRI)

Intervention type: DEVICE
Group type: OTHER
Intervention: fMRI
Description: Patient with grade 2 glioma and healthy volunteers use a brain imaging (fMRI)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: tractography
Description: Patient with grade 2 glioma and healthy volunteers use a brain imaging (tractography)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: tractography
Description: Patient with grade 2 glioma and healthy volunteers use a brain imaging (tractography)

Intervention type: OTHER
Group type: OTHER
Intervention: neuropsychological examination
Description: Patient with grade 2 glioma and healthy volunteers use a neuropsychological examination

Intervention type: OTHER
Group type: OTHER
Intervention: neuropsychological examination
Description: Patient with grade 2 glioma and healthy volunteers use a neuropsychological examination
Study: NCT01812018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel administered at 75 mg/m2, intravenously (IV), on Day 2, every 21 days for up to 4-6 consecutive cycles
Study: NCT03723525

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Package of HIV care
Description: A. Screening and management (Preventive / Pre-emptive therapies dosages) of different opportunistic infections (OI). Detail information mentioned in the manual (refer to uploaded protocol).~B. Rapid ART Initiation~1. PLHIV without suspicion or active OI: Initiate ART within seven days or same day after HIV serology disclosure~2. PLHIV with suspicion or active OI: Defer initiation if clinical symptoms suggest tuberculosis or cryptococcal meningitis. Detail information mentioned in the manual (refer to uploaded protocol).~C. Enhanced Adherence/Retention Support: mHealth: Receive text messages in mobile regarding appointment reminder (pill pick up, CD4 test, viral load test, early infant diagnosis (EID) test etc.) and general awareness messages (positive prevention, the importance of regular health check-up etc.). PLHIV with advanced HIV disease will also receive weekly/biweekly home-based adherence/ retention support linked to community care centre and community home-based care.
Study: NCT02923219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose-derived stem cells
Description: The adipose-derived stem cells therapy involve injection of patient's own adipose-derived stem cells. Local anesthetic will be applied to the face prior to the injection. For adipose-derived stem cells preparation, proper volume of fat cells will be collected from each patient just before each procedure. The stem cells will be injected into each standardized injection point in a superficial manner. The injections points are along the inferior border of cheek and mid-cheek and temple, where will be followed by 10-15 minutes of icing.
Study: NCT01994980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Default 4 days antibiotic therapy
Description: The intervention for this trial involves a shorter duration of antibiotic therapy. Specifically, a default of 4 vs. 8 days.
Study: NCT02674711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: The content of the education focus on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage. The video is 11 and ½ minutes long.
Study: NCT03835767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peanut powder and Oat flour
Description: Peanut powder with 46% protein content is manufactured by PB2. Oat flour is manufactured by GF Harvest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peanut powder and Oat flour
Description: Peanut powder with 46% protein content is manufactured by PB2. Oat flour is manufactured by GF Harvest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peanut powder and Oat flour
Description: Peanut powder with 46% protein content is manufactured by PB2. Oat flour is manufactured by GF Harvest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peanut flour and Oat flour (placebo for peanut flour)
Description: Peanut flour (12% light roast) with 50% protein content is manufactured by Byrd Mill. Oat flour is manufactured by GF Harvest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peanut flour and Oat flour (placebo for peanut flour)
Description: Peanut flour (12% light roast) with 50% protein content is manufactured by Byrd Mill. Oat flour is manufactured by GF Harvest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peanut flour and Oat flour (placebo for peanut flour)
Description: Peanut flour (12% light roast) with 50% protein content is manufactured by Byrd Mill. Oat flour is manufactured by GF Harvest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Milk Powder and Corn Starch (placebo for Milk powder)
Description: Dry milk powder with 36% protein content is manufactured by Giant Food. Corn starch is Argo brand.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Milk Powder and Corn Starch (placebo for Milk powder)
Description: Dry milk powder with 36% protein content is manufactured by Giant Food. Corn starch is Argo brand.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Milk Powder and Corn Starch (placebo for Milk powder)
Description: Dry milk powder with 36% protein content is manufactured by Giant Food. Corn starch is Argo brand.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baked milk and Rice milk (placebo for Baked milk)
Description: Baked milk will be in the form of a muffin provided by the NIH CC Nutrition Department. Rice milk is manufactured by Rice Dream brand.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baked milk and Rice milk (placebo for Baked milk)
Description: Baked milk will be in the form of a muffin provided by the NIH CC Nutrition Department. Rice milk is manufactured by Rice Dream brand.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baked milk and Rice milk (placebo for Baked milk)
Description: Baked milk will be in the form of a muffin provided by the NIH CC Nutrition Department. Rice milk is manufactured by Rice Dream brand.
Study: NCT03942328

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo high-dose EBRT
Study: NCT01149057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg intravenously, every 4 weeks for 96 weeks
Study: NCT02627963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib hydrochloride
Description: Tivozanib hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib
Study: NCT04352205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC
Study: NCT03942328

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo high-dose EBRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pheresis
Description: Undergo apheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pheresis
Description: Undergo apheresis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Autologous Dendritic Cells
Description: Given IT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Autologous Dendritic Cells
Description: Given IT
Study: NCT03471221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy Dog Visit
Description: Animal Assisted Activities (AAA) provide opportunities for motivational, educational, recreational, and/or therapeutic benefits to enhance quality of life. AAA are delivered in a variety of environments by specially trained professionals, paraprofessionals, and/or volunteers, in association with animals that meet specific criteria.~Key features of AAA are as follows:~1. Specific treatment goals are not planned for each visit.~2. Volunteers and treatment providers are not required to take detailed notes.~3. Visit content and activities are spontaneous.~4. Visit length can be as long or as short as needed.
Study: NCT04352205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Given PO
Study: NCT04432558

Intervention type: DIAGNOSTIC_TEST
Intervention: Spielberger's State-Trait Anxiety Inventory
Description: Patients will be wanted to fill the Spielberger's State-Trait Anxiety Inventory the night before the surgery.

Intervention type: OTHER
Intervention: Visual analog scale, Ramsay's sedation scale
Description: The analgesic consumption of the patients will be recorded by evaluating the pain with VAS (Visual analog scale) and sedation status with Ramsay's sedation scale in the 1st, 4th, 12th and 24th hour of postoperative period.

Intervention type: DRUG
Intervention: Tramadol, paracetamol, diclofenac sodium
Description: The analgesic consumption of the patients will be recorded
Study: NCT02989727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine tablets at dosages of 25mg/day for Week 1 and Week 2, 50mg/day for Week 3 and Week 4, 100mg/day for Week 5, and 200mg/day for Week 6, Week 7, and Week 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine tablets at dosages of 25mg/day for Week 1 and Week 2, 50mg/day for Week 3 and Week 4, 100mg/day for Week 5, and 200mg/day for Week 6, Week 7, and Week 8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo tablets